A Comparison of Dynamic Vision Between College Athletes & Controls

July 8, 2026 updated by: Aimie Kachingwe, California State University, Northridge
The purpose of this study is to establish baseline reference values for tests of static and dynamic visual acuity and gaze stabilization in collegiate athletes and non-athletes, and to determine if there are differences in vision scores between collegiate athletes and non-athletes with and without a history of concussion.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

An IRB-approved human subjects study (IRB-FY 20-339) was designed to investigate dynamic vision pre-and post-concussion in collegiate athletes. In addition to examining if there are changes in objective tests of dynamic vision after concussion, it is important to determine if there are baseline differences in dynamic vision objective tests when comparing collegiate athletes and similar-aged controls. Dynamic vision will be assessed through the administration of the Dynamic Visual Acuity (DVA) test and the Gaze Stabilization Test (GST). Baseline testing of GST and DVA is performed using the Bertec Vision Advantage TM system. Athletes are eligible to participate if they are currently enrolled students, actively participating on specified teams, provide consent to participate, and are able to complete the testing protocol. Non-athlete control subjects are students enrolled in a Doctor of Physical Therapy (DPT) program and serve as a sample of convenience.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
145

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • United States
    • California
      • Northridge, California, United States, 91330-8411
        • California State University, Northridge, Jacaranda Hall 1578, 1576, 1574

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Subjects were eligible to participate if they were currently enrolled DPT students, provided consent to participate, and were able to complete the testing protocol.

Description

Inclusion Criteria:

  • Currently a California State University Northridge student
  • Provide consent to participate Able to complete the testing protocol.

Exclusion Criteria:

  • Unable to complete entirety of testing protocol.
  • The subject is unable to attain a minimum of 85 degrees per second of horizontal head rotation when performing the DVA test.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Non-athlete college students with and without history of concussions
Non-athlete subjects included students currently enrolled in a Doctor of Physical Therapy (DPT) program served as a sample of convenience. Non-athlete subjects were excluded if they were over the age of 30 years old to minimize the effect of age in the data analysis.
Diagnostic test: Dynamic Vision Testing
Dynamic Vision Acuity is tested with the Dynamic Vision Acuity (DVA) and Gaze Stabilization Test (GST) using the Bertec Vision Advantage System.
Other Names:
  • DVA
  • GST
Students athletes with and without history of concussions
D1 student athletes currently enrolled in a large public university in the Los Angeles area. Subjects volunteered to participate in this study and currently competing in one of the following teams: Men's and Women's soccer, Men's and Women's basketball, Women's water polo or Men's volleyball. Athletes were eligible to participate if they were currently enrolled students, actively participating on the specified teams, provided consent to participate, and were able to complete the testing protocol.
Diagnostic test: Dynamic Vision Testing
Dynamic Vision Acuity is tested with the Dynamic Vision Acuity (DVA) and Gaze Stabilization Test (GST) using the Bertec Vision Advantage System.
Other Names:
  • DVA
  • GST

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Dynamic Visual Acuity (DVA)
Time Frame: August 31, 2021 - May 15, 2024
Subjects move their head at approximately 85 degrees per second per the standard test protocol. A metronome automatically generated by the computer assists in maintaining the correct head speed. When the sensor identifies 85 deg/sec, an optotype appears on the screen and the subject verbally identifies the optotype's orientation. This continues with progressively smaller sized letter until the athlete is no longer able to correctly identify the orientation. The computerized system uses a convergence algorithm to determine the accuracy of the response requiring 3 correct answers at the smallest letter size to assign a result. The computer then compares each subject's DVA score to their SVA, which is expressed a Log of minimal angle resolvable units (LogMAR). Simply, the computer considers the number of lines on an eye chart that are lost with head moving (DVA) compared to the head steady condition, known as static visual acuity (SVA)
August 31, 2021 - May 15, 2024

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Gaze Stabilization Test (GST)
Time Frame: August 31, 2021 - May 15, 2024
The subjects are asked to move their head in the horizontal plane and identify an optotype's orientation at increasing speeds. The optotype remains the same size while the head speed increases. A metronome is utilized to ensure correct head speeds which change throughout the test. When the subject reaches or exceeds the minimum threshold for velocity as measured by a wearable gyroscope attached to the forehead, the optotype appears on the screen for 75 ms, and the subject verbally identifies the direction of the optotype. The subject answers 3 of 5 trials correctly to confirm visual acuity for that velocity. The velocity of head movement begins very slowly (10 deg / second) and the rotational speed increases incrementally as long as the subject is asymptomatic and can see clearly. The test continues until the subject "fails", meaning the subject is unable to answer 3 of 5 trials correctly at a given velocity. The maximum head velocity is measured in degrees/second
August 31, 2021 - May 15, 2024
Static Visual Acuity (SVA) test
Time Frame: August 31, 2021 - May 15, 2024
The SVA tests the subject's ability to see clearly with their head held still, similar to reading a Snellen eye chart. An optotype is briefly flashed on the screen and the subject is asked to correctly identify its orientation (which directing the capital "E" is facing) as it gets progressively smaller. Once the subject gives an inaccurate answer, the computer ends the test and provides their SVA baseline value based on the smallest optotype they could identify.
August 31, 2021 - May 15, 2024

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Dynamic Visual Acuity (DVA)
Time Frame: August 31, 2021 - May 15, 2024
Log of minimal angle resolvable units (LogMAR). The number of lines on an eye chart that are lost with head moving (DVA) compared to the head steady condition, known as static visual acuity (SVA)
August 31, 2021 - May 15, 2024

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
California State University, Northridge

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Aimie Kachingwe, Dr., CSUN
  • Principal Investigator: Margaret Roller, Dr., CSUN

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
August 31, 2021

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 15, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 15, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 6, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 6, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 19, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 10, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 8, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • IRB-FY23-271

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings